Factor | Perrin.Guyomard2020 (40000)

No DOI

AMU Policy Change: Incentive Tools to Reduce AMU of Critically Important Antimicrobials

Turkey | Not Specified

6

Description

Before (2014) vs after (2016) incentive tools for reducing AMU of critically important antimicrobials, i.e. prohibition on discounts, rebates, reductions (in effect Jan 1 2015). Non-wild-type (ECOFF) considered resistant. Caecal sample @ abattoir (host su

Resistance Outcomes

Resistance Microbe Outcome
Ciprofloxacin
/
Campylobacter jejuni
See: Figure 2 AMR+ (%) AMR- (%) Total (n)
2016: AMU reduction incentive tools in place 49.99 164
2014: No AMU reduction incentive tools 48.20 174
Ciprofloxacin
/
Campylobacter jejuni
See: Section 4.2 (pg. 3, para. 5) AMR+ (%) AMR- (%) Total (n)
2016: AMU reduction incentive tools in place 58.00 164
2014: No AMU reduction incentive tools 56.00 174
Ciprofloxacin
/
Escherichia coli
See: Figure 3 and Section 4.3 (pg. 3, para. 6) AMR+ (%) AMR- (%) Total (n)
2016: AMU reduction incentive tools in place 24.40 182
2014: No AMU reduction incentive tools 21.30 239
Nalidixic Acid
/
Escherichia coli
See: Supplementary Table 1 AMR+ (%) AMR- (%) Total (n)
2016: AMU reduction incentive tools in place 21.40 182
2014: No AMU reduction incentive tools 20.10 239
Erythromycin
/
Campylobacter jejuni
See: Section 4.2 (pg. 3, para. 5) AMR+ (n) AMR- (n) Total (n)
2016: AMU reduction incentive tools in place 0 164
2014: No AMU reduction incentive tools 1 174
Gentamicin
/
Campylobacter jejuni
See: Section 4.2 (pg. 3, para. 5) AMR+ (n) AMR- (n) Total (n)
2016: AMU reduction incentive tools in place 0 164
2014: No AMU reduction incentive tools 1 174